Fred - all I said was the Biodel Phase 3 trials ended in failure. What's fuzzy about that? I'm not trying to spread any fear - just pointing out the facts! They tried to cut costs by trialling in India and screwed up. On the other matter someone said that Halo would be making a 505(b)(2) approval application. That is usually for ANDA's. If Halo is not selling a generic but a new patented Insulin compound, can they do that with a 505(b)(2) approval application. I'm also unclear as to how they could get access to say HumalinR as Eli Lilly are the only firm allowed to sell it in the US even though it is off-patent. Its rather confusing.
Market Data 
Markets 
AI
